Bosh sahifa207940 • KRX
add
Samsung Biologics Co Ltd
Yopilish kursi
1 034 000,00 ₩
Kunlik diapazon
1 015 000,00 ₩ - 1 040 000,00 ₩
Yillik diapazon
722 000,00 ₩ - 1 209 000,00 ₩
Bozor kapitalizatsiyasi
72,53 trln KRW
Oʻrtacha hajm
80,03 ming
Narx/foyda
56,68
Dividend daromadliligi
-
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (KRW) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | 1,30 trln | 37,11% |
Joriy xarajat | 241,41 mlrd | 22,51% |
Sof foyda | 375,55 mlrd | 109,38% |
Sof foyda marjasi | 28,93 | 52,75% |
Har bir ulushga tushum | 5,28 ming | 109,40% |
EBITDA | 650,09 mlrd | 78,25% |
Amaldagi soliq stavkasi | 24,80% | — |
Balans
Jami aktivlari
Jami passivlari
| (KRW) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 1,29 trln | -37,61% |
Jami aktivlari | 17,44 trln | 5,53% |
Jami passivlari | 6,16 trln | -5,47% |
Umumiy kapital | 11,28 trln | — |
Tarqatilgan aksiyalar | 71,17 mln | — |
Narxi/balansdagi bahosi | 6,52 | — |
Aktivlardan daromad | 7,00% | — |
Kapitaldan daromad | 9,70% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (KRW) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | 375,55 mlrd | 109,38% |
Operatsiyalardan naqd pul | 682,98 mlrd | 135,64% |
Sarmoyadan naqd pul | -250,22 mlrd | -142,78% |
Moliyadan naqd pul | -69,80 mlrd | 65,49% |
Naqd pulning sof oʻzgarishi | 360,84 mlrd | -47,87% |
Boʻsh pul | -103,14 mlrd | -115,61% |
Haqida
Samsung Biologics Co., Ltd. is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its core services range from late discovery to large-scale commercial manufacturing. The company focuses on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and mRNA vaccines.
The company has partnered with pharmaceutical companies such as Pfizer, GlaxoSmithKline, Eli Lilly, AstraZeneca and Bristol-Myers Squibb. Wikipedia
CEO
Tashkil etilgan
2011
Xodimlar soni
4 770
